Cat. No. 250 313 |
50 µg specific antibody, lyophilized. Affinity purified with the immunogen. Albumin was added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze! |
Applications |
Immunoprecipitation (IP); Immunoisolation or pulldown of a target molecule using an antibody. For details and product specific hints, please refer to the ”Remarks” section.', $event)" style="cursor: help;">IP: not tested yet Immunocytochemistry (ICC) on 4% PFA fixed cells. Immunoreactivity is usually revealed by fluorescence. Some antibodies require special fixation methods. For details, please refer to the “Remarks” section.', $event)" style="cursor: help;">ICC: not tested yet Immunohistochemistry (IHC) on 4% PFA perfusion fixed tissue with 24h PFA post fixation. Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate. Some antibodies require special fixation methods or antigen retrieval steps. For details, please refer to the ”Remarks” section.', $event)" style="cursor: help;">IHC: not tested yet Immunohistochemistry (IHC-P) of formalin fixed, paraffin embedded (FFPE) tissue (some antibodies require special antigen retrieval steps, please refer to the ”Remarks” section). Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate.', $event)" style="cursor: help;">IHC-P: not tested yet |
Immunogen | Synthetic peptide corresponding to AA 509 to 523 from rat EAAT3 (UniProt Id: P51907) |
Reactivity |
Reacts with: human (P43005), rat (P51907), mouse (P51906). Other species not tested yet. |
Matching control protein/peptide | 250-31P |
Data sheet | 250_313.pdf |
Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system. After the release of glutamate from synaptic vesicles into the synaptic cleft during neurotransmission, excitatory amino acid transporters (EAATs) remove extracellular glutamate to avoid excitotoxic levels (1).
Five EAATs with differential expression patterns have been described so far: EAAT1, also referred to as GLAST and SLC1A3, has neuroprotective potential following ischemia and occurs in reactive astrocytes and activated microglia. EAAT2 (GLT-1, SLC1A2) is the most abundant isoform and is primarily expressed in astrocytes. Both variants show high levels in brain and retina. EAAT3 / SLC1A1, EAAT4 / SLC1A6 and EAAT5 / SLC1A7 are expressed in neurons (2). EAAT4 shows weak expression in the forebrain and high levels in the cerebellum (3). EAAT5 primarily occurs in the retina where it locates very close to glutamate release sites. In K.O. mice flicker resolution is considerably compromised (4). Recent findings suggest that EAAT5 is an abundant isoform, expressed also in non-neuronal peripheral tissues (5).